Company intelligence / Profile preview
Cyprium Therapeutics, Inc.
New York, New York, United Statescypriumtx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Cyprium's lead product CUTX-101 (Copper Histidinate injection) has shown positive results in pivotal studies with a nearly 80% reduction in risk of death compared to historical controls. The NDA has been granted Priority Review by the FDA with a PDUFA date of September 30, 2025.
- Therapeutic areas
- Rare DiseasesMetabolic Disorders
- Modalities
- Small moleculesGene therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Sentynl Therapeutics, Inc. (Zydus Group)Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)National Institute of Neurological Disorders and Stroke (NINDS)
Beyond the preview
Go deeper on Cyprium Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cyprium Therapeutics, Inc..